
Program
WEDNESDAY, November 1st 2017
08:45 // Registration, Coffee & Mingling
09:15 // Welcome by the Norwegian Cancer Society
Elisabeth Authen Sethre
09:30-11:00 // SESSION 1 (Chair: Anders Bjartell, Lund University, Malmø, Sweden)
09:30 // Early risk prediction
Monique J. Roobol, Erasmus Medical Centre, Rotterdam, The Netherlands.
10:00 // Risk prediction in prostate cancer patients
Nicolas Mottet, University Jean Monnet, Saint-Etienne, France & Jan Oldenburg, Akershus University Hospital, Norway.
11:00 // Break
11:30-13:15 // SESSION 2 (Chair: Tuomas Mirtti, University of Helsinki, Finland)
11:30 // Biomarkers: Definition, requirements, pitfalls
Bart Kiemeney, Radboud University, Nijmegen, The Netherlands.
12:00 // Heterogeneity in Prostate Cancer
G. Steven Bova, University of Tampere and Tampere University Hospital, Finland.
12:30 // Developing clinically relevant biomarkers in prostate cancer
Stephen Pennington, UCD Conway Institute of Biomolecular and Biomedical Science Research, Dublin, Ireland.
13:00 // Patient needs
Daniel Ask, VP, Patient organisation for Prostate Cancer Patients Norway (PROFO).
13:15 // Lunch
14:15-15:45 // SESSION 3 (Chair: Antoinette Perry, UCD, Dublin, Ireland)
14:15 // Genetic variants linked to risk stratification
William B. Isaacs, Johns Hopkins University School of Medicine.
14:45 // Methylation signatures in urine
Antoinette Perry, UCD Conway Institute of Biomolecular and Biomedical Science Research, Dublin, Ireland.
15:15 // MRSI for clinical use - limitations and possibilities
Arend Heerschap, Radboud University Nijmegen Medical Center, The Netherlands.